Fulcrum Therapeutics (FULC) Income from Continuing Operations (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Income from Continuing Operations of 18891000.0 for Q1 2026, down 7.0% year-over-year from 20313088.8 in Q1 2025, and up 7.1% quarter-over-quarter from 20334000.0 in Q4 2025.
Fulcrum Therapeutics (FULC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Income from Continuing Operations data on file, last reported at 18891000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 18891000.0, down 7.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 76116000.0 (down 14824.71% YoY), and the FY2025 annual result was 74880000.0, down 669.97% from the prior year.
- Income from Continuing Operations climbed to 18891000.0 in Q1 2026 per FULC's latest filing, from 20334000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 55409000.0 in Q2 2024 and troughed at 34070000.0 in Q2 2022.
- A 5-year average of 18276588.24 and a median of 23738000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations soared 332.98% in 2024, then slumped 131.22% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 26135000.0 in 2022, then advanced by 5.28% to 24756000.0 in 2023, then jumped by 33.07% to 16568000.0 in 2024, then slipped by 22.73% to 20334000.0 in 2025, then increased by 7.1% to 18891000.0 in 2026.
- Business Quant data shows FULC's Income from Continuing Operations at 18891000.0 in Q1 2026, 20334000.0 in Q4 2025, and 19595000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | -18.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.89 Mn |
| Dec 31, 2025 | -20.33 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | -17.30 Mn |
| Mar 31, 2025 | -17.66 Mn |
| Dec 31, 2024 | -16.57 Mn |
| Sep 30, 2024 | -21.70 Mn |
| Jun 30, 2024 | 55.41 Mn |
| Mar 31, 2024 | -26.87 Mn |
| Dec 31, 2023 | -24.76 Mn |
| Sep 30, 2023 | -24.02 Mn |
| Jun 30, 2023 | -23.78 Mn |
| Mar 31, 2023 | -24.78 Mn |
| Dec 31, 2022 | -26.14 Mn |
| Sep 30, 2022 | -23.74 Mn |
| Jun 30, 2022 | -34.07 Mn |
| Mar 31, 2022 | -25.93 Mn |
| Dec 31, 2021 | -23.48 Mn |
| Sep 30, 2021 | -20.72 Mn |
| Jun 30, 2021 | -19.65 Mn |